Brief: Flerie: Anacardio Reports Results Of Phase 1B Study Of AC01

Flerie AB

09/01/2025 09:00

Jan 9 (Reuters) - Flerie AB  FLERIE.ST :
    * ANACARDIO COMPLETED PART A OF PHASE 1B/2A GOAL-HF1 STUDY
OF ORAL
GHRELIN RECEPTOR AGONIST IN PATIENTS WITH HEART FAILURE
    * AC01 WAS WELL-TOLERATED, THERE WAS CLEAR TARGET ENGAGEMENT
AND
EXPLORATORY PHARMACODYNAMIC MEASUREMENTS INDICATED INCREASED
CONTRACTILITY

Source text:  ID:nMFN1TZl0 
Further company coverage:  FLERIE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))